Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Investigation of a Novel Approach to Improve Treatment Success Rates for Tuberculosis Patients in Senegal

This study has been completed.
Sponsor:
Information provided by:
Institut de Recherche pour le Developpement
ClinicalTrials.gov Identifier:
NCT00412009
First received: December 14, 2006
Last updated: NA
Last verified: December 2006
History: No changes posted
  Purpose

Tuberculosis (TB) patients who receive inadequate treatment or do not complete therapy are more likely to remain infectious, thus contributing to the continuous spread of TB infection in communities. Despite the widespread use of Directly Observed Therapy, defaulters remain an important problem in TB control programmes. In Sénégal, defaulters rate reach 30%, which is hampering dramatically the effectiveness of control. New strategies to deliver treatment to TB patients and ensure proper adherence that are adapted to the local situations are urgently needed.

Objectives

The overall objective of the project is to improve tuberculosis treatment success rates in Sénégal. The specific objectives are:

  1. to assess the current situation of tuberculosis (TB) in Sénégal
  2. to identify the determinants of cure,
  3. to develop measures to improve patient’s compliance with the treatment that are adapted to the local situation, acceptable, affordable and sustainable
  4. to evaluate the impact of these measures on TB control.

Methods

The proposed research seeks to develop and test innovative methods to improve cure rates in TB patients. It will explore the factors of success of TB treatment using inter-disciplinary approach, integrating social sciences and economic analyses into TB research. The project is composed of 3 comprehensive phases:

  • Phase 1: baseline assessment of the TB situation.
  • Phase 2: anthropological study, investigating various domains contributing to patients cure using a range of qualitative research methods. At the end of this investigation, it is expected that determinants of care will be clearly identified. On this basis, suitable methods for improving patients’ adherence to treatment will be tailored and developed.
  • Phase 3: these methods will be tested and compared using a cluster randomised controlled trial design, in populations served by defined health centres. Their efficacy will be measured in terms of improvement of the classical TB control programme indicators (cure rate, defaulter rate, failure rate, death rates). The methods will also be evaluated on their acceptability by the TB patients and the communities and on their feasibility (duration : 24 months).

Expected results:

Methods to improve patients’ adherence to treatment that are affordable, acceptable and sustainable will be developed and tested according to qualitative and quantitative criteria.


Condition Intervention Phase
Tuberculosis
Procedure: Comprehensive package of activities
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Investigation of a Novel Approach to Improve Adherence to Treatment and Treatment Success Rates for Tuberculosis Patients in Senegal

Resource links provided by NLM:


Further study details as provided by Institut de Recherche pour le Developpement:

Primary Outcome Measures:
  • TB treatment success rate (cure + completed treatment)
  • Treatment defaulting rates

Secondary Outcome Measures:
  • treatment failure rate
  • death rate

Estimated Enrollment: 1500
Study Start Date: May 2003
Estimated Study Completion Date: January 2005
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   15 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • newly diagnosed sputum-smear positive pulmonary TB (at least two positive specimens), aged 15 years or more, and living in the district served by the District Health Centre.

Exclusion Criteria:

  • Smear-negative tuberculosis cases
  • extra-pulmonary tuberculosis cases
  • TB re-treatment cases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00412009

Locations
Senegal
Programme National de Lutte Anti-tuberculeuse
Dakar, Senegal
Sponsors and Collaborators
Institut de Recherche pour le Developpement
Investigators
Principal Investigator: Moustapha Ndir, MD Programme de Lutte anti-tuberculeuse, Dakar, Senegal
Principal Investigator: Christian Lienhardt, MD Institut de Recherche pour le Developpement, Paris, France
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00412009     History of Changes
Other Study ID Numbers: PAL+ 2671
Study First Received: December 14, 2006
Last Updated: December 14, 2006
Health Authority: France: Ministry of Health

Keywords provided by Institut de Recherche pour le Developpement:
tuberculosis
control
treatment
adherence

Additional relevant MeSH terms:
Tuberculosis
Actinomycetales Infections
Bacterial Infections
Gram-Positive Bacterial Infections
Mycobacterium Infections

ClinicalTrials.gov processed this record on November 20, 2014